• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

3.650 +0.900 (+32.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
May 20, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
May 20, 2026
Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses 
Via TheNewswire.com
News headline image
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
May 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
May 18, 2026
WHO Emergency Declaration of Ebola Outbreak and Ongoing Mpox Developments Reinforce the Importance of Diversified Vaccine Supply and Scalable U.S.-Based Manufacturing Capabilities 
Via TheNewswire.com
News headline image
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
May 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 02, 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen 
Via NewMediaWire
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 02, 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen 
Via TheNewswire.com
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
May 18, 2026
ATLANTA, GA - May 18, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has entered into a... 
Via TheNewswire.com
News headline image
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
May 14, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
May 14, 2026
ATLANTA, GA - May 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,... 
Via TheNewswire.com
Topics Supply Chain
GeoVax Provides Update on GEO-MVA Program
March 25, 2026
Clinical Product Release Testing Completed in Support of Pivotal Phase 3 Trial 
Via TheNewswire.com
News headline image
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
May 13, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
May 13, 2026
Company Expands Strategic Immuno-Oncology Positioning Around Tumor Microenvironment Modulation, Checkpoint Enhancement, and Multi-Tumor Development Potential 
Via TheNewswire.com
News headline image
GeoVax Announces a Warrant Inducement Transaction
May 07, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
May 07, 2026
ATLANTA, GA - May 7, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant... 
Via TheNewswire.com
News headline image
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 06, 2026
Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization 
Via TheNewswire.com
News headline image
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 29, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 29, 2026
Near-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation 
Via TheNewswire.com
News headline image
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
April 27, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
April 27, 2026
Positioned to Enhance Efficacy of Checkpoint Inhibitors and Next-Generation Oncology Modalities Across Solid Tumors 
Via TheNewswire.com
News headline image
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 15, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 15, 2026
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine) 
Via TheNewswire.com
News headline image
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 14, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy Supply Chain
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 14, 2026
Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide 
Via TheNewswire.com
Topics Economy Supply Chain
News headline image
GeoVax Announces a Warrant Inducement Transaction
March 31, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
March 31, 2026
ATLANTA, GA - March 31, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,... 
Via TheNewswire.com
News headline image
GeoVax Provides Update on GEO-MVA Program
March 25, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
March 12, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
March 12, 2026
Peer-Reviewed Article Describes Clinical and Immunologic Rationale for Dual-Antigen MVA-Based Vaccine Designed to Address Limitations of First-Generation COVID-19 Vaccines in Highly Vulnerable... 
Via TheNewswire.com
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap